| Nov 21 |
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
|
| Nov 20 |
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
|
| Nov 18 |
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
|
| Nov 12 |
Atossa Therapeutics GAAP EPS of -$0.06 in-line
|
| Nov 12 |
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 8 |
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go
|
| Nov 5 |
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
|
| Nov 4 |
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
|
| Oct 31 |
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
|
| Oct 21 |
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
|
